

























QP-Insights®
















Cases by subjects

Displaying 1 to 10 out of 10243 subjects

<input type="checkbox"/>	Subject name	Actions	eCDF	Segmented	Public tags	Personal tags	Exams number	Case
<input type="checkbox"/>	CTL-01-001	    		<input checked="" type="checkbox"/>	NOCLC		9	
<input type="checkbox"/>	CTL-01-002	    		<input checked="" type="checkbox"/>	NOCLC		15	
<input type="checkbox"/>	CTL-02-003	    		<input checked="" type="checkbox"/>	SCLC		1	

Exam name	Actions	Status	Segmented	Public tags	Personal tags	Exam date	Timepoint	Modality	Files
	    	Finished	<input checked="" type="checkbox"/>			7/6/20	Baseline	CT	

Series name	Segmentations	Public tags	Personal tags	Series number	Modality	Number of images
Abdomen, Brain, Chest, Pelvis	  			6	CT	192

<input type="checkbox"/>	CTL-02-004	Actions	Status	Segmented	Public tags	Personal tags	Exam date	Timepoint	Modality	Files
<input type="checkbox"/>	CTL-02-005	    								
<input type="checkbox"/>	CTL-02-006	    								


QP-Insights®

From unstructured imaging data to precision medicine decisions

Discover QP-Insights®

Critical insights remain hidden within your imaging data. Medical imaging data is still fragmented, hard to access, and not fully leveraged: limiting its impact on clinical and development decisions.

All-in-one imaging data platform that enables precision medicine by transforming raw data into a structured, decision-ready environment across drug development and patient care.



- IMAGING EXAMS AT DIFFERENT TIMEPOINTS (FPFV, screening, tumor assessments, EOT, follow-ups, LPLV, etc.)
- DIFFERENT IMAGING MODALITIES (CT, MRI, PET, SPECT, etc.)
- BLINDED INDEPENDENT CENTRALIZED READINGS AND LOCAL SITE READINGS REPORTS, RE-ASSESSMENTS & OTHERS (i.e., surgery reports)


- LABORATORY DATA
- ELECTRONIC MEDICAL & HEALTH RECORDS
- HISTOPATHOLOGY DATA
- OBSERVATIONAL STUDIES DATA

- FPFV: First Patient First Visit.
- EOT: End Of Treatment.
- LPLV: Last Patient Last Visit.
- CT: Computed Tomography.
- MRI: Magnetic Resonance Imaging.
- PET: Positron Emission Tomography.
- SPECT: Single photon emission computed tomography.

1. Data integration & management

Seamlessly ingest, standardize, and manage multimodal imaging and clinical data in a unified, secure environment.

- Supports all imaging modalities in DICOM (CT, MRI, PET, SPECT, and more).
- Integrated electronic case report forms (eCRF) tailored to each protocol and Electronic Data Capture systems connectivity to capture and synchronize structured clinical data alongside imaging data.
- Automated pseudonymization, categorization, and quality control at ingestion (individual, batch, or PACS).



2. Data exploitation

→ DICOM VIEWER WITH AI-ASSISTED READING AND ANNOTATION.


AI-supported RECIST:

Semi-automated response assessment with AI-powered lesion detection and longitudinal tracking across timepoints. Includes 3D volumetric tumor analysis as a complementary layer to traditional bidimensional measurements.



PET Imaging:

Automated detection and quantitative analysis of lesions across PET tracers (such as PSMA, or FDG).



→ ADVANCED RADIOMICS FOR QUANTITATIVE IMAGING FEATURE EXTRACTION

Characterizes lesion heterogeneity, morphology, texture, and functional behavior.


Integrates PET-derived molecular imaging features and functional MRI-derived parameters.

Supports the development of diagnostic, predictive, and prognostic imaging biomarkers for clinical research, drug development and patient management.

Cohort Builder: define your study population in seconds.


Enables real-time identification of eligible subjects:

- Advanced multi-parameter search across clinical variables, DICOM metadata, and imaging-derived biomarkers.
- New patient cohorts creation according to your target population.



3. Structured reports, ready for action

Structured, exportable outputs designed to support clinical decisions and regulatory submissions.



Prostate Cancer Panel
Risk of metastasis
Version 1.0.0

Physician: not given | Patient ID: Q05AAD7
Site: Biomarker: unclassified
Study Date: 25-10-2011 | Age (months): 71
Report Date: 10-08-2023 | Sex: |

Predicted Risk Score
High

Patient Characteristics

Clinical variables	Value
Age	71
PSA (ng/ml)	12.02
BRCA2 status	Mutated
Histology subtype	Acinar adenocarcinoma
Gleason score	7
PIRADS	5
cT	cT2c
cN	cN0
cM	cM0
Neural invasion	Yes
Vascular invasion	No
Lymphatic invasion	No

Imaging variables

Radiomics features	Value
Skewness	0.55
Maximum 2D diameter	0
GLCM informational measure of correlation	0.83
GLSZM zone percentage	0.00
GLSZM gray-level uniformity	5400.65

Representative tissue

Clinically significant prostate cancer lesions segmentation, defining the area where the radiomics features are extracted.

Risk prediction

Clinical and radiomics features: importance of the clinical and radiomics features to predict patient's risk of metastasis.

Features importance for metastasis risk prediction

Features	Impact on Prediction
PSA	+6.23
BRCA2	+4.81
FirstOrder-Skewness	+2.84
Shape-Maximum2DDiameter	+2.24
Neural_Invasion	+1.59
Gleason score	+1.4
cT	+1.08
GLSZM-ZonePercentage	+0.17

This device does not provide a definitive diagnosis. Results shall be reviewed by a qualified physician.
© 2023 Quibim S.L. All rights reserved. Specifications are subject to change without notice.

One platform to make your data actionable

Three biomarker types: diagnostic, predictive, prognostic. The first step toward imaging-based companion diagnostics.

QP-Insights® transforms large-scale imaging and clinical datasets into actionable evidence across the full lifecycle, from drug development decisions to clinical patient management.

Turn your data into clinically and regulatory-ready imaging biomarkers, with Quibim supporting regulatory pathway and commercialization.

Contact us: contact@quibim.com

USA: +1 718.308.1418

Europe: +34 961 243 225

Faster trial timelines

Automated data handling streamlines ingestion, processing, and analysis, reducing operational delays and accelerating key development milestones.

Scalable & cloud-native

Deployed on cloud-based infrastructures with global accessibility, unlimited storage, scalability, and role-based access control.

Better patient stratification

Cross-trial cohort enrichment enables identification and selection of the right patients from the start.

AI-driven radiomics unlocks novel diagnostic, predictive, and prognostic imaging biomarkers, supporting adaptive trial design and precision medicine strategies.

Regulatory confidence

Developed and validated in accordance with GAMP® 5 principles. The system includes a robust audit trail to support data integrity requirements in regulated GxP environments. Designed to support compliance with GDPR, HIPAA, and 21CFRPart11.

